請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49421
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 邱麗珠 | |
dc.contributor.author | Li-Wei Tung | en |
dc.contributor.author | 童力威 | zh_TW |
dc.date.accessioned | 2021-06-15T11:27:54Z | - |
dc.date.available | 2021-08-26 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-18 | |
dc.identifier.citation | Adamantidis, A.R., Zhang, F., Aravanis, A.M., Deisseroth, K. & de Lecea, L. (2007) Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature, 450, 420-424.
Ahn, K., McKinney, M.K. & Cravatt, B.F. (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev., 108, 1687-1707. Alcami, P., Franconville, R., Llano, I. & Marty, A. (2012) Measuring the firing rate of high-resistance neurons with cell-attached recording. J Neurosci, 32, 3118-3130. Alvarez, C.E. & Sutcliffe, J.G. (2002) Hypocretin is an early member of the incretin gene family. Neurosci. Lett., 324, 169-172. Ammoun, S., Holmqvist, T., Shariatmadari, R., Oonk, H.B., Detheux, M., Parmentier, M., Akerman, K.E. & Kukkonen, J.P. (2003) Distinct recognition of OX1 and OX2 receptors by orexin peptides. J. Pharmacol. Exp. Ther., 305, 507-514. Aston-Jones, G., Smith, R.J., Sartor, G.C., Moorman, D.E., Massi, L., Tahsili-Fahadan, P. & Richardson, K.A. (2010) Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction. Brain Res., 1314, 74-90. Atwood, B.K. & Mackie, K. (2010) CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol, 160, 467-479. Baimel, C., Bartlett, S.E., Chiou, L.C., Lawrence, A.J., Muschamp, J.W., Patkar, O., Tung, L.W. & Borgland, S.L. (2014) Orexin/hypocretin role in reward: implications for opioid and other addictions. Br J Pharmacol. Baimel, C. & Borgland, S.L. (2015) Orexin Signaling in the VTA Gates Morphine-Induced Synaptic Plasticity. The Journal of Neuroscience, 35, 7295-7303. Bisogno, T., Melck, D., Bobrov, M., Gretskaya, N.M., Bezuglov, V.V., De Petrocellis, L. & Di Marzo, V. (2000) N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J., 351 Pt 3, 817-824. Blankman, J.L., Simon, G.M. & Cravatt, B.F. (2007a) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol, 14, 1347-1356. Blankman, J.L., Simon, G.M. & Cravatt, B.F. (2007b) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol, 14, 1347-1356. Borgland, S.L., Taha, S.A., Sarti, F., Fields, H.L. & Bonci, A. (2006) Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron, 49, 589-601. Boutrel, B., Kenny, P.J., Specio, S.E., Martin-Fardon, R., Markou, A., Koob, G.F. & de Lecea, L. (2005) Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A, 102, 19168-19173. Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., Mueller, C., Nayler, O., van Gerven, J., de Haas, S.L., Hess, P., Qiu, C., Buchmann, S., Scherz, M., Weller, T., Fischli, W., Clozel, M. & Jenck, F. (2007) Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med, 13, 150-155. Cadas, H., Gaillet, S., Beltramo, M., Venance, L. & Piomelli, D. (1996) Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci, 16, 3934-3942. Cami, J. & Farre, M. (2003) Drug addiction. N. Engl. J. Med., 349, 975-986. Chemelli, R.M., Willie, J.T., Sinton, C.M., Elmquist, J.K., Scammell, T., Lee, C., Richardson, J.A., Williams, S.C., Xiong, Y., Kisanuki, Y., Fitch, T.E., Nakazato, M., Hammer, R.E., Saper, C.B. & Yanagisawa, M. (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell, 98, 437-451. Chiou, L.C., Lee, H.J., Ho, Y.C., Chen, S.P., Liao, Y.Y., Ma, C.H., Fan, P.C., Fuh, J.L. & Wang, S.J. (2010) Orexins/hypocretins: pain regulation and cellular actions. Curr Pharm Des, 16, 3089-3100. Cippitelli, A., Bilbao, A., Hansson, A.C., del Arco, I., Sommer, W., Heilig, M., Massi, M., Bermudez-Silva, F.J., Navarro, M., Ciccocioppo, R. & de Fonseca, F.R. (2005) Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci, 21, 2243-2251. Crombag, H.S., Johnson, A.W., Zimmer, A.M., Zimmer, A. & Holland, P.C. (2010) Deficits in sensory-specific devaluation task performance following genetic deletions of cannabinoid (CB1) receptor. Learn. Mem., 17, 18-22. Dallman, M.F., Akana, S.F., Levin, N., Walker, C.D., Bradbury, M.J., Suemaru, S. & Scribner, K.S. (1994) Corticosteroids and the control of function in the hypothalamo-pituitary-adrenal (HPA) axis. Ann. N. Y. Acad. Sci., 746, 22-31; discussion 31-22, 64-27. Davis, S.F., Williams, K.W., Xu, W., Glatzer, N.R. & Smith, B.N. (2003) Selective enhancement of synaptic inhibition by hypocretin (orexin) in rat vagal motor neurons: implications for autonomic regulation. J Neurosci, 23, 3844-3854. de Lecea, L., Kilduff, T.S., Peyron, C., Gao, X., Foye, P.E., Danielson, P.E., Fukuhara, C., Battenberg, E.L., Gautvik, V.T., Bartlett, F.S., 2nd, Frankel, W.N., van den Pol, A.N., Bloom, F.E., Gautvik, K.M. & Sutcliffe, J.G. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A, 95, 322-327. De Vries, T.J., de Vries, W., Janssen, M.C. & Schoffelmeer, A.N. (2005) Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behav Brain Res, 161, 164-168. De Vries, T.J., Shaham, Y., Homberg, J.R., Crombag, H., Schuurman, K., Dieben, J., Vanderschuren, L.J. & Schoffelmeer, A.N. (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med, 7, 1151-1154. Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A. & Mechoulam, R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949. Di Chiara, G., Bassareo, V., Fenu, S., De Luca, M.A., Spina, L., Cadoni, C., Acquas, E., Carboni, E., Valentini, V. & Lecca, D. (2004) Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology, 47 Suppl 1, 227-241. Di Marzo, V. & De Petrocellis, L. (2010) Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr. Med. Chem., 17, 1430-1449. Di Marzo, V. & Petrosino, S. (2007) Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol., 18, 129-140. Epstein, D.H., Preston, K.L., Stewart, J. & Shaham, Y. (2006) Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl). 189, 1-16. Fadel, J. & Deutch, A.Y. (2002) Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area. Neuroscience, 111, 379-387. Fattore, L., Spano, M.S., Cossu, G., Deiana, S. & Fratta, W. (2003) Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci, 17, 1723-1726. Fride, E. (2008) Multiple roles for the endocannabinoid system during the earliest stages of life: pre- and postnatal development. J. Neuroendocrinol., 20 Suppl 1, 75-81. Gebremedhin, D., Lange, A.R., Campbell, W.B., Hillard, C.J. & Harder, D.R. (1999) Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol., 276, H2085-2093. Gerashchenko, D., Horvath, T.L. & Xie, X.S. (2011) Direct inhibition of hypocretin/orexin neurons in the lateral hypothalamus by nociceptin/orphanin FQ blocks stress-induced analgesia in rats. Neuropharmacology, 60, 543-549. Goparaju, S.K., Ueda, N., Yamaguchi, H. & Yamamoto, S. (1998) Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett., 422, 69-73. Guindon, J. & Hohmann, A.G. (2009) The endocannabinoid system and pain. CNS & neurological disorders drug targets, 8, 403-421. Hadvary, P., Sidler, W., Meister, W., Vetter, W. & Wolfer, H. (1991) The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J Biol Chem, 266, 2021-2027. Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D.E., Kustanovich, I. & Mechoulam, R. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A, 98, 3662-3665. Hanus, L., Gopher, A., Almog, S. & Mechoulam, R. (1993) Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem., 36, 3032-3034. Harris, G.C. & Aston-Jones, G. (2006) Arousal and reward: a dichotomy in orexin function. Trends Neurosci., 29, 571-577. Harris, G.C., Wimmer, M. & Aston-Jones, G. (2005) A role for lateral hypothalamic orexin neurons in reward seeking. Nature, 437, 556-559. Harris, G.C., Wimmer, M., Randall-Thompson, J.F. & Aston-Jones, G. (2007) Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. Behav Brain Res, 183, 43-51. Heifets, B.D. & Castillo, P.E. (2009) Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol, 71, 283-306. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R. & Rice, K.C. (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci, 11, 563-583. Herkenham, M., Lynn, A.B., Little, M.D., Johnson, M.R., Melvin, L.S., de Costa, B.R. & Rice, K.C. (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 87, 1932-1936. Hillard, C.J. & Jarrahian, A. (2000) The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem. Phys. Lipids, 108, 123-134. Ho, S.Y., Chen, C.H., Liu, T.H., Chang, H.F. & Liou, J.C. (2012) Protein kinase mzeta is necessary for cocaine-induced synaptic potentiation in the ventral tegmental area. Biol Psychiatry, 71, 706-713. Ho, Y.C., Lee, H.J., Tung, L.W., Liao, Y.Y., Fu, S.Y., Teng, S.F., Liao, H.T., Mackie, K. & Chiou, L.C. (2011) Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. J Neurosci, 31, 14600-14610. Hollander, J.A., Lu, Q., Cameron, M.D., Kamenecka, T.M. & Kenny, P.J. (2008) Insular hypocretin transmission regulates nicotine reward. Proc Natl Acad Sci U S A, 105, 19480-19485. Houchi, H., Babovic, D., Pierrefiche, O., Ledent, C., Daoust, M. & Naassila, M. (2005) CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology, 30, 339-349. Howlett, A.C. (2005) Cannabinoid receptor signaling. Handbook of experimental pharmacology, 53-79. Johnson, P.L., Truitt, W., Fitz, S.D., Minick, P.E., Dietrich, A., Sanghani, S., Traskman-Bendz, L., Goddard, A.W., Brundin, L. & Shekhar, A. (2010) A key role for orexin in panic anxiety. Nat Med, 16, 111-115. Johnson, S.W. & North, R.A. (1992) Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J Physiol, 450, 455-468. Kalivas, P.W. & O'Brien, C. (2008) Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology, 33, 166-180. Kang, J.E., Lim, M.M., Bateman, R.J., Lee, J.J., Smyth, L.P., Cirrito, J.R., Fujiki, N., Nishino, S. & Holtzman, D.M. (2009) Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science, 326, 1005-1007. Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M. & Watanabe, M. (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev, 89, 309-380. Katz, J.L. & Higgins, S.T. (2003) The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology (Berl). 168, 21-30. Kim, J., Isokawa, M., Ledent, C. & Alger, B.E. (2002) Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci, 22, 10182-10191. Koob, G.F. (2008) A role for brain stress systems in addiction. Neuron, 59, 11-34. Koob, G.F. & Volkow, N.D. (2010) Neurocircuitry of addiction. Neuropsychopharmacology, 35, 217-238. Korotkova, T.M., Sergeeva, O.A., Eriksson, K.S., Haas, H.L. & Brown, R.E. (2003) Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins. J Neurosci, 23, 7-11. Kukkonen, J.P. (2012) Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol, 304, C2-32. Kukkonen, J.P., Holmqvist, T., Ammoun, S. & Akerman, K.E. (2002) Functions of the orexinergic/hypocretinergic system. Am J Physiol Cell Physiol, 283, C1567-1591. Labouebe, G., Liu, S., Dias, C., Zou, H., Wong, J.C., Karunakaran, S., Clee, S.M., Phillips, A.G., Boutrel, B. & Borgland, S.L. (2013) Insulin induces long-term depression of ventral tegmental area dopamine neurons via endocannabinoids. Nat Neurosci, 16, 300-308. Lawrence, A.J., Cowen, M.S., Yang, H.J., Chen, F. & Oldfield, B. (2006a) The orexin system regulates alcohol-seeking in rats. Br J Pharmacol, 148, 752-759. Lawrence, A.J., Cowen, M.S., Yang, H.J., Chen, F. & Oldfield, B. (2006b) The orexin system regulates alcohol-seeking in rats. Br J Pharmacol, 148, 752-759. Lee, H.J., Chang, L.Y., Ho, Y.C., Teng, S.F., Hwang, L.L., Mackie, K. & Chiou, L.C. (2016) Stress induces analgesia via orexin 1 receptor-initiated endocannabinoid/CB1 signaling in the mouse periaqueductal gray. Neuropharmacology, 105, 577-586. Leishman, E., Cornett, B., Spork, K., Straiker, A., Mackie, K. & Bradshaw, H.B. (2016) Broad impact of deleting endogenous cannabinoid hydrolyzing enzymes and the CB1 cannabinoid receptor on the endogenous cannabinoid-related lipidome in eight regions of the mouse brain. Pharmacol. Res. Leung, D., Saghatelian, A., Simon, G.M. & Cravatt, B.F. (2006) Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry (Mosc). 45, 4720-4726. Li, Y., Gao, X.B., Sakurai, T. & van den Pol, A.N. (2002) Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron, 36, 1169-1181. Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., Qiu, X., de Jong, P.J., Nishino, S. & Mignot, E. (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 98, 365-376. Liu, J., Wang, L., Harvey-White, J., Huang, B.X., Kim, H.Y., Luquet, S., Palmiter, R.D., Krystal, G., Rai, R., Mahadevan, A., Razdan, R.K. & Kunos, G. (2008) Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology, 54, 1-7. Ludanyi, A., Hu, S.S., Yamazaki, M., Tanimura, A., Piomelli, D., Watanabe, M., Kano, M., Sakimura, K., Magloczky, Z., Mackie, K., Freund, T.F. & Katona, I. (2011) Complementary synaptic distribution of enzymes responsible for synthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in the human hippocampus. Neuroscience, 174, 50-63. Lutz, B. (2009) Endocannabinoid signals in the control of emotion. Current opinion in pharmacology, 9, 46-52. Ma, X., Zubcevic, L., Bruning, J.C., Ashcroft, F.M. & Burdakov, D. (2007) Electrical inhibition of identified anorexigenic POMC neurons by orexin/hypocretin. J Neurosci, 27, 1529-1533. Mahler, S.V., Smith, R.J., Moorman, D.E., Sartor, G.C. & Aston-Jones, G. (2012) Multiple roles for orexin/hypocretin in addiction. Prog Brain Res, 198, 79-121. Margolis, E.B., Coker, A.R., Driscoll, J.R., Lemaitre, A.I. & Fields, H.L. (2010) Reliability in the identification of midbrain dopamine neurons. PLoS One, 5, e15222. Marinelli, S., Pascucci, T., Bernardi, G., Puglisi-Allegra, S. & Mercuri, N.B. (2005) Activation of TRPV1 in the VTA excites dopaminergic neurons and increases chemical- and noxious-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology, 30, 864-870. Martin-Fardon, R., Zorrilla, E.P., Ciccocioppo, R. & Weiss, F. (2010) Role of innate and drug-induced dysregulation of brain stress and arousal systems in addiction: Focus on corticotropin-releasing factor, nociceptin/orphanin FQ, and orexin/hypocretin. Brain Res., 1314, 145-161. Martin, M., Ledent, C., Parmentier, M., Maldonado, R. & Valverde, O. (2000) Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci, 12, 4038-4046. Matyas, F., Urban, G.M., Watanabe, M., Mackie, K., Zimmer, A., Freund, T.F. & Katona, I. (2008) Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology, 54, 95-107. McKinney, M.K. & Cravatt, B.F. (2005) Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem., 74, 411-432. Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R. & et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 50, 83-90. Mori, K., Kim, J. & Sasaki, K. (2011) Electrophysiological effects of orexin-B and dopamine on rat nucleus accumbens shell neurons in vitro. Peptides, 32, 246-252. Munro, S., Thomas, K.L. & Abu-Shaar, M. (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365, 61-65. Narita, M., Nagumo, Y., Hashimoto, S., Khotib, J., Miyatake, M., Sakurai, T., Yanagisawa, M., Nakamachi, T., Shioda, S. & Suzuki, T. (2006) Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci, 26, 398-405. Nishino, S., Ripley, B., Overeem, S., Lammers, G.J. & Mignot, E. (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet, 355, 39-40. Nitish Bhatia, Partha Pratim Maiti, Abhinit Choudhary, Atul Tuli, Daljit Masih, Mohd. Masih Uzzaman Khan, Tasneem Ara, Jaggi, A.S. & (2011) Animal models in the study of stress: A review NSHM Journal of Pharmacy and Healthcare Management, 02, 42-50. Pan, B., Hillard, C.J. & Liu, Q.S. (2008) Endocannabinoid signaling mediates cocaine-induced inhibitory synaptic plasticity in midbrain dopamine neurons. J Neurosci, 28, 1385-1397. Pandey, R., Mousawy, K., Nagarkatti, M. & Nagarkatti, P. (2009) Endocannabinoids and immune regulation. Pharmacol. Res., 60, 85-92. Paulus, M.P. (2007) Neural basis of reward and craving--a homeostatic point of view. Dialogues in clinical neuroscience, 9, 379-387. Paxinos, G. & Franklin, K. (2001) The Mouse Brain in Stereotaxic Coordinates (Deluxe Edition). Academic Press, California, USA. Pertwee, R., Griffin, G., Hanus, L. & Mechoulam, R. (1994) Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur. J. Pharmacol., 259, 115-120. Pertwee, R.G. (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem., 17, 1360-1381. Plaza-Zabala, A., Maldonado, R. & Berrendero, F. (2012) The hypocretin/orexin system: implications for drug reward and relapse. Mol. Neurobiol., 45, 424-439. Porter, A.C., Sauer, J.M., Knierman, M.D., Becker, G.W., Berna, M.J., Bao, J., Nomikos, G.G., Carter, P., Bymaster, F.P., Leese, A.B. & Felder, C.C. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 301, 1020-1024. Re, G., Barbero, R., Miolo, A. & Di Marzo, V. (2007) Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet. J., 173, 21-30. Richards, J.K., Simms, J.A., Steensland, P., Taha, S.A., Borgland, S.L., Bonci, A. & Bartlett, S.E. (2008) Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Psychopharmacology (Berl). 199, 109-117. Riegel, A.C. & Lupica, C.R. (2004) Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci, 24, 11070-11078. Rodriguez de Fonseca, F., Navarro, M., Gomez, R., Escuredo, L., Nava, F., Fu, J., Murillo-Rodriguez, E., Giuffrida, A., LoVerme, J., Gaetani, S., Kathuria, S., Gall, C. & Piomelli, D. (2001) An anorexic lipid mediator regulated by feeding. Nature, 414, 209-212. Ross, S. & Peselow, E. (2009) The neurobiology of addictive disorders. Clin. Neuropharmacol., 32, 269-276. Saario, S.M. & Laitinen, J.T. (2007) Monoglyceride lipase as an enzyme hydrolyzing 2-arachidonoylglycerol. Chemistry & biodiversity, 4, 1903-1913. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., Williams, S.C., Richardson, J.A., Kozlowski, G.P., Wilson, S., Arch, J.R., Buckingham, R.E., Haynes, A.C., Carr, S.A., Annan, R.S., McNulty, D.E., Liu, W.S., Terrett, J.A., Elshourbagy, N.A., Bergsma, D.J. & Yanagisawa, M. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell, 92, 573-585. Sakurai, T. & Mieda, M. (2011) Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol. Sci., 32, 451-462. Schlicker, E. & Kathmann, M. (2008) Presynaptic neuropeptide receptors. Handbook of experimental pharmacology, 409-434. Shalev, U., Erb, S. & Shaham, Y. (2010) Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking. Brain Res., 1314, 15-28. Simon, G.M. & Cravatt, B.F. (2008) Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem, 283, 9341-9349. Smith, R.J., See, R.E. & Aston-Jones, G. (2009) Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. Eur J Neurosci, 30, 493-503. Stella, N. & Piomelli, D. (2001) Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol., 425, 189-196. Stuart, J.M., Paris, J.J., Frye, C. & Bradshaw, H.B. (2013) Brain levels of prostaglandins, endocannabinoids, and related lipids are affected by mating strategies. International journal of endocrinology, 2013, 436252. Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A. & Waku, K. (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 215, 89-97. Takai, T., Takaya, T., Nakano, M., Akutsu, H., Nakagawa, A., Aimoto, S., Nagai, K. & Ikegami, T. (2006) Orexin-A is composed of a highly conserved C-terminal and a specific, hydrophilic N-terminal region, revealing the structural basis of specific recognition by the orexin-1 receptor. Journal of peptide science : an official publication of the European Peptide Society, 12, 443-454. Taslimi, Z., Haghparast, A., Hassanpour-Ezatti, M. & Safari, M.S. (2011) Chemical stimulation of the lateral hypothalamus induces conditioned place preference in rats: Involvement of OX1 and CB1 receptors in the ventral tegmental area. Behav Brain Res, 217, 41-46. Thannickal, T.C., Moore, R.Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M., Cornford, M. & Siegel, J.M. (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron, 27, 469-474. Tzeng, W.Y., Chuang, J.Y., Lin, L.C., Cherng, C.G., Lin, K.Y., Chen, L.H., Su, C.C. & Yu, L. (2013) Companions reverse stressor-induced decreases in neurogenesis and cocaine conditioning possibly by restoring BDNF and NGF levels in dentate gyrus. Psychoneuroendocrinology, 38, 425-437. Uramura, K., Funahashi, H., Muroya, S., Shioda, S., Takigawa, M. & Yada, T. (2001) Orexin-a activates phospholipase C- and protein kinase C-mediated Ca2+ signaling in dopamine neurons of the ventral tegmental area. Neuroreport, 12, 1885-1889. Urbanska, A., Sokolowska, P., Woldan-Tambor, A., Bieganska, K., Brix, B., Johren, O., Namiecinska, M. & Zawilska, J.B. (2012) Orexins/hypocretins acting at Gi protein-coupled OX 2 receptors inhibit cyclic AMP synthesis in the primary neuronal cultures. J. Mol. Neurosci., 46, 10-17. van den Pol, A.N., Gao, X.B., Obrietan, K., Kilduff, T.S. & Belousov, A.B. (1998) Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci, 18, 7962-7971. Viscomi, M.T., Oddi, S., Latini, L., Pasquariello, N., Florenzano, F., Bernardi, G., Molinari, M. & Maccarrone, M. (2009) Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci, 29, 4564-4570. Vittoz, N.M. & Berridge, C.W. (2006) Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: involvement of the ventral tegmental area. Neuropsychopharmacology, 31, 384-395. Viveros, M.P., de Fonseca, F.R., Bermudez-Silva, F.J. & McPartland, J.M. (2008) Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. Endocrine, metabolic & immune disorders drug targets, 8, 220-230. Wang, B., You, Z.B. & Wise, R.A. (2009) Reinstatement of cocaine seeking by hypocretin (orexin) in the ventral tegmental area: independence from the local corticotropin-releasing factor network. Biol Psychiatry, 65, 857-862. Winsky-Sommerer, R., Boutrel, B. & de Lecea, L. (2005) Stress and arousal: the corticotrophin-releasing factor/hypocretin circuitry. Mol. Neurobiol., 32, 285-294. Winsky-Sommerer, R., Yamanaka, A., Diano, S., Borok, E., Roberts, A.J., Sakurai, T., Kilduff, T.S., Horvath, T.L. & de Lecea, L. (2004) Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. J Neurosci, 24, 11439-11448. Wise, R.A. (1996) Addictive drugs and brain stimulation reward. Annu Rev Neurosci, 19, 319-340. Woldan-Tambor, A., Bieganska, K., Wiktorowska-Owczarek, A. & Zawilska, J.B. (2011) Activation of orexin/hypocretin type 1 receptors stimulates cAMP synthesis in primary cultures of rat astrocytes. Pharmacological reports : PR, 63, 717-723. Wong, K.K., Ng, S.Y., Lee, L.T., Ng, H.K. & Chow, B.K. (2011) Orexins and their receptors from fish to mammals: a comparative approach. Gen. Comp. Endocrinol., 171, 124-130. Yahyavi-Firouz-Abadi, N. & See, R.E. (2009) Anti-relapse medications: preclinical models for drug addiction treatment. Pharmacol. Ther., 124, 235-247. Yamanaka, A., Beuckmann, C.T., Willie, J.T., Hara, J., Tsujino, N., Mieda, M., Tominaga, M., Yagami, K., Sugiyama, F., Goto, K., Yanagisawa, M. & Sakurai, T. (2003) Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron, 38, 701-713. Zhao, L. & Levine, E.S. (2014) BDNF-endocannabinoid interactions at neocortical inhibitory synapses require phospholipase C signaling. J. Neurophysiol., 111, 1008-1015. Zimmer, A., Zimmer, A.M., Hohmann, A.G., Herkenham, M. & Bonner, T.I. (1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A, 96, 5780-5785. Zucker, R.S. & Regehr, W.G. (2002) Short-term synaptic plasticity. Annu Rev Physiol, 64, 355-405. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/49421 | - |
dc.description.abstract | 已有諸多的文獻指出食慾素系統包含食慾素A和B及其受體,OX1R和OX2R,已知與飲食、回饋、醒覺的生理機能調控有關。而食慾素神經元的在大腦中的分布主要集中於Lateral hypothalamus (LH)、Perifonical area (PFA)以及Dorsomedial hypothalamus (DMH)並透過其軸突向其他腦區廣泛延伸,其中包括腹側被蓋區(VTA),該核區主要與獎勵回饋的生理功能有關,具有相當多的多巴胺型神經元容易受成癮性物質影響。然而,食慾素對腹側被蓋區的調控作用乃至於藥物成癮可說是知之甚少。
從本實驗室先前的文獻已知,食慾素在中腦導水管周圍灰質具有新型鎮痛機制:在急性壓力下LH中的食慾素神經元活化導致下游中腦導水管周圍灰質的食慾素大量上升,透過激活突觸後OX1R,Gq蛋白偶聯受體,進而活化磷脂酶C(PLC),甘油二酯脂肪酶(DAGL)產生內生性大麻酯(2-AG)達到抑制突觸前抑制性神經訊息傳導產生止痛的效果。從而推測如果OX 1R-PLC-DAGL-2-AG這樣的調控機制也存在於腹側被蓋區多巴胺型神經元,或許有相當高的可能性透過抑制多巴胺型神經元上游的抑制性神經元突觸訊息傳導而導致壓力誘發藥物成癮復發的現象,因此本篇論文將透過電生理、行為模式以及生物化學與病理染色檢測來驗證該假說。 首先,從大鼠腦片的電生理數據證實,高濃度的食慾素A(100 nM)可以有效的抑制腹側被蓋區中多巴胺型神經元上游的抑制型神經元突觸訊息而非興奮性神經元傳導。並從Paired pulse ratio (PPR)與mIPSC記錄中觀察到高濃度的食慾素處理下PPR顯著性的上升以及mIPSC中頻率的增加來推斷這樣的抑制性現象係透過突觸前而非突觸後,而這樣的調控透過一系列上述假設的訊息傳導路徑的拮抗劑SB 334867(3μM)(OX1R 拮抗劑) ; Edelfosine(5μM)(PLC 抑製劑) ; THL (Tetrahydrolipstatin, 10μM, 2-AG合成酶(DAGL)抑製劑) ; AM251(3μM)(CB1R 拮抗劑)所逆轉。此外,為求實驗完整性透過直接量測並觀察到在實際生理狀態下食慾素A確實透過上述機轉強化對多巴胺型神經元的活性,而這一項關鍵性的證據搭配上述這些結果初步推論,食慾素A能藉由OX1R-PLC-DAGL-2-AG,這樣的調控機制達到抑制多巴胺型神經元上游的抑制型神經元突觸訊息傳導,進而解釋食慾素系統在藥物成癮行為的貢獻。 已有文獻證實給予實驗動物急性束縛性壓力可活化大腦外側下視丘中食慾素系統,因此論文的第二部分將藉由急性束縛性壓力引發藥物成癮復發動物行為模式(場地制約性偏好測試:實驗動物經過3天的腹腔注射古柯鹼(20 mg/kg)導致與實驗設備發生場地制約化的現象後再經過3天的強制戒斷後,最後一天給予30分鐘的急性束縛壓力)搭配藥理學方法驗證我們上述在體外所發現的新機轉在實驗動物上能夠確實發生。我們觀察到急性束縛性壓力造成位於LH的食欲素神經元大量活化而PFA或DMH且與復發程度息息相關進而使下游腹側被蓋區的內生性食慾素與相對應生成的大麻酯的釋放量上升導致藥物成癮性復發的現象。這樣的現象也分別以系統性或是針對腹側被蓋區的局部給予上述於電生理實驗所用的OX1R拮抗劑、DAGL抑製劑、CB1R 拮抗劑來證實假說確實存在。從結果得知,不論是全身性或是局部性給予拮抗劑皆可以顯著性預防壓力所導致的藥物成癮性復發行為,為求實驗設計完善亦透過CB1R基因踢除的小鼠與局部腹側被蓋區給予食慾素A以及CB1R 拮抗劑來模擬急性束縛性壓力引發藥物成癮復發的機轉,此外,已有部分文獻指出不同的壓力條件所牽涉到的機轉將有所不同,其中研究最為透徹的促腎上腺皮質激素釋放因子(Cortical releasing factor, CRF)系統在某些壓力(如電刺激或是危及生命形式的壓力)所誘發藥物成癮復發的機轉扮演重要角色並非本篇論文所提及的食慾素系統,因此,在行為試驗的最後一部分將驗證食慾素系統以及CRF系統在急性束縛性壓力所引起藥物成癮復發中的角色比重,從結果得知,在腹側被蓋區中食慾素系統相較於CRF系統在急性束縛性壓力下所引起的藥物成癮復發中發揮至關重要的影響力。 從這些結果再次證明這項嶄新的神經生理機轉能在急性束縛性壓力下主要導致LH食慾素神經元的活化使下游腹側被蓋區的食慾素大量上升而非CRF系統,進而透過多巴胺型神經元上OX 1R-PLC-DAGL的訊息傳導路徑產生內生性大麻酯2-AG導致突觸前抑制性訊息傳導受到抑制,最終引發藥物成癮復發現象。 | zh_TW |
dc.description.abstract | The orexin system, consisting of orexin A and B and their receptors, OX1R and OX2R, is implicated in the regulation of several neuronal functions, such as motivation, feeding, reward and pain. Among these, the role of orexins in reward regulation is especially noteworthy. Orexin neurons, expressed exclusively in the perifornical area (PFA), dorsomedial (DMH) and lateral hypothealamus (LH), project widely throughout the brain including the ventral tegmental area (VTA), an important reward processing site where dopamine neuron plasticity can be altered by addictive substances. Orexins have been known to play an important role in the reward system. However, how orexins regulate the VTA dopaminergic activity to provoke drug craving, especially under a stressful condition, remains unclear. We have previously revealed a novel analgesic mechanism of orexins in the periaqueductal gray (PAG) that mediates the stress-induced analgesia phenomenon. That is, under stress, orexin neurons are activated to release orexins in the PAG. Then, orexins activate postsynaptic OX1Rs, a family of Gq-protein coupled receptors, resulting in synthesis of 2-arachydonoylglycerol (2-AG) via phospholipase C (PLC)-diacylglycerol lipase (DAGL) enzymatic pathway. 2-AG, an endocannabinoid, then produces retrograde inhibition of GABA release (disinhibition) by activating presynaptic cannabinoid 1 receptors (CB1Rs). Here, we examined whether this OX1R-PLC-DAGL-2-AG retrograde disinhibition signaling also exists in VTA dopamine neurons and can contribute to stress-induced extinguished cocaine seeking. We used electrophysiological and behavioral approaches to examine effects of orexin A on inhibitory postsynaptic currents (IPSCs) in dopamine neurons of rat VTA slices and on cocaine-conditioned place preference (CPP) in mice, respectively,.
In electrophysiological studies, we found that orexin A (100 nM) depressed GABAergic IPSCs, but not excitatory PSCs, in VTA dopamine neurons and increased paired pulse ratio of paired IPSCs, suggesting a presynaptic effect. Orexin A also decreased the freqquency, but not amplitude, of miniature IPSCs, suggesting orexin A decreases GABA release. The IPSC depressant effect of orexin A was reversed or prevented by SB334867 (3 | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T11:27:54Z (GMT). No. of bitstreams: 1 ntu-105-F99443001-1.pdf: 4012161 bytes, checksum: 39ac71c9dfefc687c973148558bff8df (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 致謝 I
摘要 III ABSTRACT V ABBREVIATION VIII INTRODUCTION 1 THE SUBSTANCE ABUSE 1 THE HYPOCRETIN/OREXIN SYSTEM 2 THE ENDOGENOUS CANNABINOID SYSTEM (ECS) 7 THE HYPOTHESIS 11 METHODS 13 ELECTROPHYSIOLOGY STUDY 13 HYPERPOLARIZATION-ACTIVATED INWARD (IH) CURRENT 14 TH IMMUNOFLUORESCENCE IN VTA SLICES 15 COCAINE CONDITIONED PLACE PREFERENCE (CPP) 16 EXTINCTION OF COCAINE CPP 17 ACUTE RESTRAINT STRESS-INDUCED REINSTATEMENT OF EXTINGUISHED COCAINE CPP 17 OREXIN A-INDUCED REINSTATEMENT OF EXTINGUISHED COCAINE CPP 18 BILATERAL INTRA-VTA CANNULATION 18 DRUG ADMINISTRATION 18 DOUBLE IMMUNOHISTOCHEMICAL STAINING 19 MEASUREMENT OF OREXIN A LEVELS IN THE VTA 20 MEASUREMENT OF ENDOCANNABINOID LEVELS IN THE VTA 21 DRUGS 22 DATA ANALYSIS 24 RESULTS 25 OREXIN A DEPRESSED IPSCS, BUT NOT EPSCS, OF VTA DOPAMINE NEURONS VIA OX1RS 25 OREXIN A INHIBITED GABAERGIC TRANSMISSION PRESYNAPTICALLY 26 OREXIN A INHIBITED GABA RELEASE THROUGH CB1RS 26 OREXIN A DEPRESSED IPSCS VIA A GQPCR-PLC-DAGL-2AG CASCADE 27 THE 2-AG-MEDIAED DISINHIBITORY EFFECT OF OREXIN A IN VTA DOPAMINE NEURONS IS CONCENTRATION-DEPENDENT 27 OREXIN A INCREASED VTA NEURONAL FIRING INDIRECTLY VIA CB1RS 28 THE OX1R-2-AG-CB1R CASCADE IN STRESS-INDUCED COCAINE RELAPSE 29 RESTRAINT STRESS REINSTATED EXTINGUISHED COCAINE CPP IN MICE 30 STRESS DID NOT INDUCE COCAINE RELAPSE IN CNR1-DEFICIENT MICE 30 SYSTEMIC OX1R AND CB1R BLOCKADE PREVENTED COCAINE RELAPSE 31 VTA OX1RS, CB1RS AND DAGL IN STRESS-INDUCED COCAINE RELAPSE 31 OREXIN A (I.VTA.) INDUCED COCAINE RELAPSE VIA CB1RS 31 RESTRAINT STRESS-INDUCED COCAINE RELAPSE IS MAINLY MEDIATED BY OREXIN A, BUT NOT CRF, IN THE MOUSE VTA 32 ACUTE RESTRAINT STRESS ACTIVATED LH OREXIN NEURONS 33 ACUTE RESTRAINT STRESS ELEVATED VTA OREXIN A AND 2-AG LEVELS 34 DISCUSSION 35 OREXIN A DECREASES GABA RELEASE VIA OX1RS, BUT NOT OX2RS, AND CB1RS IN VTA DOPAMINERGIC NEURONS 35 OX1R-INITIATED AND 2AG-MEDIATED VTA DISINHIBITION CONTRIBUTES TO RESTRAINT STRESS-INDUCED COCAINE RELAPSE 36 INVOLVEMENT OF OREXIN NEURONS IN THE LH, BUT NOT PFA/DMH, IN ACUTE RESTRAINT STRESS-INDUCED DRUG RELAPSE 37 THE ROLE OF THE VTA OREXIN SYSTEM IN DRUG RELAPSE 39 REFERENCES 41 FIGURES AND TABLES 59 FIGURE 1. IDENTIFICATION OF DOPAMINERGIC NEURONS IN VTA SLICES. 60 FIGURE 2. OREXIN A DEPRESSED INHIBITORY BUT NOT EXCITATORY NEURO-TRANSMISSION IN VTA, VIA A PRESYNAPTIC MECHANISM. 62 FIGURE 3. OREXIN A DEPRESSED IPSCS IN VTA SLICES THROUGH OX1RS, BUT NOT OX2RS, VIA A PRESYNAPTIC MECHANISM. 64 FIGURE 4. OREXIN A DECREASED THE FREQUENCY, BUT NOT THE AMPLITUDE, OF MIPSCS. 66 FIGURE 5. OREXIN A-INDUCED IPSC DEPRESSION WAS REVERSED BY A CB1R ANTAGONIST, AND WAS MIMICKED AND OCCLUDED BY A CB1R AGONIST. 68 FIGURE 6. OREXIN A-INDUCED IPSC DEPRESSION WAS PREVENTED BY INHIBITORS OF G-PROTEINS, PLCΒ OR DAGL, AND WAS ENHANCED BY A MAGL INHIBITOR. 70 FIGURE 7. OREXIN A INHIBITED GABAERGIC TRANSMISSION IN VTA DOPAMINERGIC NEURONS EXCEPT AT CONCERNTRATIONS AROUND 30 NM. 72 FIGURE 8. OREXIN A INCREASED THE FIRING RATE OF VTA DOPAMINERGIC NEURONS THROUGH CB1RS. 74 FIGURE 9. OREXIN A DEPRESSED IPSCS IN DOPAMINERGIC NEURONS OF MOUSE VTA SLICES IN A MANNER REVERSED BY A CB1R ANTAGONIST. 76 FIGURE 10. RESTRAINT STRESS OR INTRA-VTA MICROINJECTION OF OREXIN A REINSTATED EXTINGUISHED COCAINE-CONDITIONED PLACE PREFERENCE (CPP) IN WILD-TYPE, BUT NOT IN CNR1 KO MICE OR IN MICE PRETREATED WITH AN OX1R OR CB1R ANTAGONIST. 78 FIGURE 11. RESTRAINT STRESS INDUCED COCAINE REINSTATEMENT MAINLY THROUGH OX 1R-2-AG-CB1R PATHWAY PREDOMINANTLY RATHER THAN VIA CRF SYSTEM IN VTA DOPAMINE NEURONS. 81 FIGURE 12. RESTRAINT STRESS INCREASED THE NUMBER OF C-FOS-EXPRESSING OREXIN NEURONS IN THE LATERAL HYPOTHALAMUS AND OREXIN A LEVELS IN THE VTA. 83 FIGURE 13. A SCHEMATIC ILLUSTRATION OF HOW STRESS-RELEASED OREXINS INDUCE AN ENDOCANNABINOID-MEDIATED RELAPSE FOR COCAINE-SEEKING. 85 TABLE 1. ENDOCANNABINOID LEVELS IN THE VTA OF EXTINGUISHED MICE WITH AND WITHOUT RESTRAINT STRESS. 87 BIBLIOGRAPHY 88 | |
dc.language.iso | en | |
dc.title | 壓力如何撩起癮頭:食慾素誘發內源性大麻素促使成癮腦區多巴胺神經元失控 | zh_TW |
dc.title | How stress provokes drug craving: Orexin-initiated endocannabinoid-mediated dopaminergic disinhibition in the ventral tagmental area | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 簡伯武,許桂森,游一龍,陳景宗,陳慧諴 | |
dc.subject.keyword | 藥物成癮,壓力,食慾素,內生性大麻,電生理,場地制約化行為, | zh_TW |
dc.subject.keyword | stress induced reinstatement,orexin,endocannabinoid,electrophysiology,VTA,CPP, | en |
dc.relation.page | 88 | |
dc.identifier.doi | 10.6342/NTU201603064 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 3.92 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。